Xiaohua Wu
Shanghai Medical College of Fudan University(CN)University of Electronic Science and Technology of China(CN)Northwestern Polytechnical University(CN)Sichuan University(CN)West China Hospital of Sichuan University(CN)Fudan University Shanghai Cancer Center(CN)Institute of Electronics(CN)Shijiazhuang Yiling Pharmaceutical (China)(CN)Ministry of Agriculture and Rural Affairs(CN)South China University of Technology(CN)
Publications by Year
Research Areas
PARP inhibition in cancer therapy, Ovarian cancer diagnosis and treatment, Endometrial and Cervical Cancer Treatments, BRCA gene mutations in cancer, Quantum Information and Cryptography
Most-Cited Works
- → Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39)(2021)385 cited
- → Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial(2023)282 cited
- → Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial☆(2021)198 cited
- → China’s new strategy to block Schistosoma japonicum transmission: experiences and impact beyond schistosomiasis(2009)179 cited
- → Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial(2023)178 cited